Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, Single-center, Phase Ib Study Assessing IBI308 Monotherapy for Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer

Trial Profile

Open, Single-center, Phase Ib Study Assessing IBI308 Monotherapy for Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Sep 2019 Results (data cut off: June 15th, 2019) assessing the safety and efficacy of neoadjuvant sintilimab in Chinese patients with resectable NSCLCpresented at the 20th World Conference on Lung Cancer
    • 04 Jun 2019 Results (n=22; as of Jan 2019) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2019 Results published in the Innovent Biologics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top